47 related articles for article (PubMed ID: 23298266)
1. Lymphatic biomarkers in primary melanomas as predictors of regional lymph node metastasis and patient outcomes.
Pasquali S; van der Ploeg AP; Mocellin S; Stretch JR; Thompson JF; Scolyer RA
Pigment Cell Melanoma Res; 2013 May; 26(3):326-37. PubMed ID: 23298266
[TBL] [Abstract][Full Text] [Related]
2. Lymphatic invasion as a prognostic biomarker in primary cutaneous melanoma.
Xu X; Gimotty PA; Guerry D; Karakousis G; Elder DE
Methods Mol Biol; 2014; 1102():275-86. PubMed ID: 24258984
[TBL] [Abstract][Full Text] [Related]
3. Cross‑talk between lymphangiogenesis and malignant melanoma cells: New opinions on tumour drainage and immunization (Review).
Ju W; Cai HH; Zheng W; Li DM; Zhang W; Yang XH; Yan ZX
Oncol Lett; 2024 Feb; 27(2):81. PubMed ID: 38249813
[TBL] [Abstract][Full Text] [Related]
4. IL-1RA inhibits esophageal carcinogenesis and lymphangiogenesis via downregulating VEGF-C and MMP9.
Shen Z; Zhang P; Zhang W; Luo F; Xu H; Chen S; Kang M
Funct Integr Genomics; 2023 May; 23(2):164. PubMed ID: 37198330
[TBL] [Abstract][Full Text] [Related]
5. From simplicity to complexity in current melanoma models.
Michielon E; de Gruijl TD; Gibbs S
Exp Dermatol; 2022 Dec; 31(12):1818-1836. PubMed ID: 36103206
[TBL] [Abstract][Full Text] [Related]
6. Biomarkers for Diagnosis, Prognosis and Response to Immunotherapy in Melanoma.
Puglisi R; Bellenghi M; Pontecorvi G; Pallante G; Carè A; Mattia G
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34207514
[TBL] [Abstract][Full Text] [Related]
7. Lymphangiogenesis-inducing vaccines elicit potent and long-lasting T cell immunity against melanomas.
Sasso MS; Mitrousis N; Wang Y; Briquez PS; Hauert S; Ishihara J; Hubbell JA; Swartz MA
Sci Adv; 2021 Mar; 7(13):. PubMed ID: 33762337
[TBL] [Abstract][Full Text] [Related]
8. Cellular Origins of the Lymphatic Endothelium: Implications for Cancer Lymphangiogenesis.
Gutierrez-Miranda L; Yaniv K
Front Physiol; 2020; 11():577584. PubMed ID: 33071831
[TBL] [Abstract][Full Text] [Related]
9. Primary tumor characteristics and next-generation sequencing mutations as biomarkers for melanoma immunotherapy response.
Loo K; Gauvin G; Soliman I; Renzetti M; Deng M; Ross E; Luo B; Wu H; Reddy S; Olszanski AJ; Farma JM
Pigment Cell Melanoma Res; 2020 Nov; 33(6):878-888. PubMed ID: 32564504
[TBL] [Abstract][Full Text] [Related]
10. ELK3 expressed in lymphatic endothelial cells promotes breast cancer progression and metastasis through exosomal miRNAs.
Kim KS; Park JI; Oh N; Cho HJ; Park JH; Park KS
Sci Rep; 2019 Jun; 9(1):8418. PubMed ID: 31182803
[TBL] [Abstract][Full Text] [Related]
11. Stromal inflammatory cells are associated with poorer prognosis in primary cutaneous melanoma.
Yun SJ; Liu S; Buckley M; Wang T; Jin S; Karakousis G; Peters MG; Elder DE; Gimotty PA; Xu X
Hum Pathol; 2019 Jun; 88():78-86. PubMed ID: 30965022
[TBL] [Abstract][Full Text] [Related]
12. Two Birds, One Stone: Double Hits on Tumor Growth and Lymphangiogenesis by Targeting Vascular Endothelial Growth Factor Receptor 3.
Hsu MC; Pan MR; Hung WC
Cells; 2019 Mar; 8(3):. PubMed ID: 30901976
[TBL] [Abstract][Full Text] [Related]
13. IFNγ-activated dermal lymphatic vessels inhibit cytotoxic T cells in melanoma and inflamed skin.
Lane RS; Femel J; Breazeale AP; Loo CP; Thibault G; Kaempf A; Mori M; Tsujikawa T; Chang YH; Lund AW
J Exp Med; 2018 Dec; 215(12):3057-3074. PubMed ID: 30381467
[TBL] [Abstract][Full Text] [Related]
14. Lymphatic vessel density is associated with CD8
Bordry N; Broggi MAS; de Jonge K; Schaeuble K; Gannon PO; Foukas PG; Danenberg E; Romano E; Baumgaertner P; Fankhauser M; Wald N; Cagnon L; Abed-Maillard S; Maby-El Hajjami H; Murray T; Ioannidou K; Letovanec I; Yan P; Michielin O; Matter M; Swartz MA; Speiser DE
Oncoimmunology; 2018; 7(8):e1462878. PubMed ID: 30221058
[TBL] [Abstract][Full Text] [Related]
15. Lymph microvascularization as a prognostic indicator in neuroblastoma.
Tadeo I; Gamero-Sandemetrio E; Berbegall AP; Gironella M; Ritort F; Cañete A; Bueno G; Navarro S; Noguera R
Oncotarget; 2018 May; 9(40):26157-26170. PubMed ID: 29899849
[TBL] [Abstract][Full Text] [Related]
16. Lymphatic vessels regulate immune microenvironments in human and murine melanoma.
Lund AW; Wagner M; Fankhauser M; Steinskog ES; Broggi MA; Spranger S; Gajewski TF; Alitalo K; Eikesdal HP; Wiig H; Swartz MA
J Clin Invest; 2016 Sep; 126(9):3389-402. PubMed ID: 27525437
[TBL] [Abstract][Full Text] [Related]
17. Lymphatic Vessels, Inflammation, and Immunity in Skin Cancer.
Lund AW; Medler TR; Leachman SA; Coussens LM
Cancer Discov; 2016 Jan; 6(1):22-35. PubMed ID: 26552413
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathology significance of podoplanin immunoreactivity in esophageal squamous cell carcinoma.
Ma W; Wang K; Yang S; Wang J; Tan B; Bai B; Wang N; Jia Y; Jia M; Cheng Y
Int J Clin Exp Pathol; 2014; 7(5):2361-71. PubMed ID: 24966946
[TBL] [Abstract][Full Text] [Related]
19. Surface antigen profiles of leukocytes and melanoma cells in lymph node metastases are associated with survival in AJCC stage III melanoma patients.
Kaufman KL; Mactier S; Armstrong NJ; Mallawaaratchy D; Byrne SN; Haydu LE; Jakrot V; Thompson JF; Mann GJ; Scolyer RA; Christopherson RI
Clin Exp Metastasis; 2014 Apr; 31(4):407-21. PubMed ID: 24435119
[TBL] [Abstract][Full Text] [Related]
20. Data set for pathology reporting of cutaneous invasive melanoma: recommendations from the international collaboration on cancer reporting (ICCR).
Scolyer RA; Judge MJ; Evans A; Frishberg DP; Prieto VG; Thompson JF; Trotter MJ; Walsh MY; Walsh NM; Ellis DW;
Am J Surg Pathol; 2013 Dec; 37(12):1797-814. PubMed ID: 24061524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
